TYRA · Tyra Biosciences, Inc. · Insider Trading

These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

Includes restricted stock units.

The previously filed Form 4 overstated the number of securities beneficially owned by the Reporting Person in column 5, due to a clerical error, which has been corrected on this Form 4.

The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 19.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Held directly by the Fund.

These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

Includes restricted stock units.

These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

Includes restricted stock units.

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $20.5550 to $20.6488. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to Jake Simson's continuous service to the Issuer through each vesting date.

RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

Under Mr. Simson's arrangement with the Adviser, Mr. Simson holds the option for the benefit of the Fund, the Nexus Fund, and the Account. Mr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.

The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Includes RSUs.

Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Includes RSUs.

Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Includes RSUs.

1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

25% of the shares subject to the option shall vest on May 5, 2027, and 1/48th of the total number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Includes RSUs.

1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Includes RSUs.

1/36th of the total number of shares of common stock subject to the option vest monthly following April 16, 2026, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Fully vested.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.25 to $38.125. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Fully vested.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.95 to $37.11. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $32.98 to $33.85. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $31.02 to $31.75. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $28.9131 to $29.23. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $27.9083 to $28.84. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Alta Partners NextGen Fund II, L.P. ("APNG II") on June 26, 2025.

These securities are held directly by APNG II. The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $22.06 to $23.03. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

25% of the shares subject to the option shall vest on December 1, 2026, and 1/48th of the total number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Alta Partners NextGen Fund II, L.P. ("APNG II") on June 26, 2025.

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $20.25 to $21.24. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

These securities are held directly by APNG II. The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.04 to $16.68. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.24. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $17.00. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.06 to $17.09. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.13. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.02. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

1/48th of the shares subject to the option vest monthly following August 7, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

1/48th of the shares subject to the option vest monthly following August 7, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

1/48th of the shares subject to the option vest monthly following August 7, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

25% of the shares subject to the option shall vest on August 7, 2026, and 1/36th of the remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.